KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (2016 - 2026)

Gilead Sciences filings provide 17 years of EPS (Weighted Average and Diluted) readings, the most recent being $1.74 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 22.54% to $1.74 in Q4 2025 year-over-year; TTM through Dec 2025 was $6.77, a 1729.73% increase, with the full-year FY2025 number at $6.78, up 1684.21% from a year prior.
  • EPS (Weighted Average and Diluted) hit $1.74 in Q4 2025 for Gilead Sciences, down from $2.43 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.43 in Q3 2025 to a low of -$3.34 in Q1 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $1.25 (2021), compared with a mean of $1.01.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 3900.0% in 2023 and later crashed 517.5% in 2024.
  • Gilead Sciences' EPS (Weighted Average and Diluted) stood at $0.3 in 2021, then surged by 333.33% to $1.3 in 2022, then fell by 13.08% to $1.13 in 2023, then grew by 25.66% to $1.42 in 2024, then grew by 22.54% to $1.74 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $1.74 (Q4 2025), $2.43 (Q3 2025), and $1.56 (Q2 2025) per Business Quant data.